Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Исследование энтректиниба (Rxdx-101) у детей и подростков с местнораспространенными или метастатическими солидными или первичными опухолями ЦНС и/или у которых нет удовлетворительных вариантов лечения (STARTRK-NG)

18 сентября 2026 г. обновлено: Hoffmann-La Roche

Фаза 1/2, открытое исследование с повышением дозы и увеличением дозы энтректиниба (Rxdx-101) в педиатрии с местнораспространенными или метастатическими солидными или первичными опухолями ЦНС и/или у которых нет удовлетворительных вариантов лечения

This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.

Обзор исследования

Статус

Активный, не рекрутирующий

Вмешательство/лечение

Тип исследования

Интервенционный

Регистрация (Действительный)

69

Фаза

  • Фаза 2
  • Фаза 1

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Германия, 69120
        • Universitaetsklinikum Heidelberg
      • Hong Kong, Гонконг, 00000
        • Hong Kong Children's Hospital
      • Madrid, Испания, 28009
        • Hospital Infantil Universitario Nino Jesus
    • Lombardy
      • Milan, Lombardy, Италия, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
    • Ontario
      • Toronto, Ontario, Канада, M5G 1X8
        • The Hospital for Sick Children
      • Beijing, Китай
        • Beijing Children's Hospital, Capital Medical University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Китай, 200082
        • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
      • London, Соединенное Королевство, SW3 6JJ
        • Royal Marsden Hospital (Sutton)
      • Newcastle upon Tyne, Соединенное Королевство, NE1 4LP
        • Royal Victoria Infirmary
    • California
      • La Jolla, California, Соединенные Штаты, 92093-0706
        • University of California San Diego
      • San Francisco, California, Соединенные Штаты, 94158
        • UCSF Benioff Children's Hospital
    • Colorado
      • Aurora, Colorado, Соединенные Штаты, 80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta, Georgia, Соединенные Штаты, 30322
        • Egleston Children's Hospital at Emory University Atlanta
    • Illinois
      • Chicago, Illinois, Соединенные Штаты, 60637
        • University of Chicago
    • Maryland
      • Baltimore, Maryland, Соединенные Штаты, 21205
        • Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, Соединенные Штаты, 02215
        • Dana Farber Cancer Institute
    • Missouri
      • St Louis, Missouri, Соединенные Штаты, 63110
        • Washington University,St. Louis Children's Hospital
    • New York
      • New York, New York, Соединенные Штаты, 10065
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Columbus, Ohio, Соединенные Штаты, 43205
        • Nationwide Children's Hospital
    • Oregon
      • Portland, Oregon, Соединенные Штаты, 97239
        • Oregon Health & Science Uni
    • Pennsylvania
      • Philadelphia, Pennsylvania, Соединенные Штаты, 19104
        • Children's Hospital of Philadelphia
    • Tennessee
      • Memphis, Tennessee, Соединенные Штаты, 38105
        • St. Jude Children'S Research Hospital
    • Texas
      • Houston, Texas, Соединенные Штаты, 77030
        • Texas Children's Cancer and Hematology Center
    • Utah
      • Salt Lake City, Utah, Соединенные Штаты, 84113
        • Primary Children's Hospital
      • Lyon, Франция, 69373
        • Centre Leon Berard
      • Marseille, Франция, 13385
        • Hôpital de la Timone, Oncologie Pédiatrique

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 1 секунда до 18 лет (Ребенок, Взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  1. Disease status:

    • Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1

    • Phase 2 portion:

      • Part B: Participants must have measurable or evaluable disease, as defined by RANO
      • Part C (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale
      • Part D: Participants must have measurable or evaluable disease, as defined by RECIST v1.1
      • Part E (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale or RANO
  2. Tumor type:

    • Phase 1 portion:

      * Part A: Relapsed or refractory extracranial solid tumors

    • Phase 2 portion

      • Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
      • Part D: Extracranial solid tumors (including NB) with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
  3. Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse

  4. Archival tumor tissue from diagnosis or, preferably, at relapse

  5. Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at least 4 weeks

  6. Prior therapy: Participants must have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options for solid tumors and primary CNS tumors that are neurotrophic tyrosine receptor kinase (NTRK) or ROS1 fusion-positive

  7. Participants must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment

  8. Adequate organ and neurologic function

  9. Females of childbearing potential must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Agreement to remain abstinent or use use combined contraceptive methods prior to study entry, for the duration of study participation and in the following 90 days after discontinuation of study treatment.

  10. For male participants with a female partner of childbearing potential or a pregnant female partner: Agreement to remain abstinent or use a condom during the treatment period and for at least 3 months after the last dose of study drug

Exclusion Criteria:

  1. Receiving other experimental therapy
  2. Known congenital long QT syndrome
  3. History of recent (3 months) symptomatic congestive heart failure or ejection fraction ≤50% at screening
  4. Known active infections
  5. Familial or personal history of congenital bone disorders, bone metabolism alterations or osteopenia
  6. Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
  7. Prior treatment with approved or investigational TRK or ROS1 inhibitors
  8. Known hypersensitivity to entrectinib or any of the other excipients of the investigational medicinal product
  9. Patients with NB with bone marrow space-only disease
  10. Incomplete recovery from acute effects of any surgery prior to treatment.
  11. Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
  12. Other severe acute or chronic medical or psychiatric condition or lab abnormality that may increase the risk associated with study participation, drug administration or may interfere with the interpretation of study results.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Нерандомизированный
  • Интервенционная модель: Одногрупповое задание
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Активный компаратор: Extracranial solid tumors harboring NTRK1/2/3,

Arm closed for further enrollment

ROS1, ALK non-gene fusion molecular alterations

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Другие имена:
  • RXDX-101
Активный компаратор: CNS tumors harboring- NTRK1/2/3, ROS1, ALK

Arm closed for further enrollment

molecular alterations, including gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Другие имена:
  • RXDX-101
Активный компаратор: Neuroblastoma

Arm closed for further enrollment

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Другие имена:
  • RXDX-101
Активный компаратор: Non-neuroblastoma, extracranial solid tumors

Arm closed for further enrollment

harboring - NTRK1/2/3, ROS1, ALK gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Другие имена:
  • RXDX-101
Активный компаратор: Any participant unable to swallow capsules

Arm closed for further enrollment

Any participant who otherwise meet all other eligibility criteria

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Другие имена:
  • RXDX-101
Активный компаратор: Expansion: CNS tumors harboring NTRK1/2/3, ROS1

gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Другие имена:
  • RXDX-101
Активный компаратор: Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1

NTRK 1,2,3 and ROS1 fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Другие имена:
  • RXDX-101

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Maximum Tolerated Dose (MTD)
Временное ограничение: Approximately 6 months

Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03)

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Временное ограничение: Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Временное ограничение: Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)
Временное ограничение: Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules
Временное ограничение: Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Cohort B: Objective Response Rate (ORR)
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR

Approximately 6 months
Cohort D: ORR
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR

Approximately 6 months

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03
Временное ограничение: Approximately 24 months

AE, ECG and Labs assessed by NCI CTCAE v4.03

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F1 Formulation
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using minitablets/F15
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F1 Formulation
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F06 Formulation given intact
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using minitablets/F15
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F1 Formulation
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F06 Formulation given intact
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F06 Formulation administered via feeding tube
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using minitablets/F15
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F1 Formulation
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F06 Formulation given intact
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F06 Formulation administered via feeding tube
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using minitablets/F15
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F1 Formulation
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F06 Formulation given intact
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using minitablets/F15
Временное ограничение: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Cohort A, D, or E: Clinical Benefit Rate (CBR)
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: CBR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: CBR
Временное ограничение: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Progression-free Survival (PFS)
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: PFS
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: PFS
Временное ограничение: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Overall Survival (OS)
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1

Approximately 6 months
Cohort B or E: OS
Временное ограничение: Approximately 6 months

Assessed by RANO

Approximately 6 months
Cohort A, D, or E: ORR
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: ORR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: ORR
Временное ограничение: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Time to response (TTR)
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: TTR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: TTR
Временное ограничение: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Duration of Response (DOR)
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: DOR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: DOR
Временное ограничение: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Временное ограничение: Approximately 6 months

Assessed by RANO per the investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): ORR
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): ORR
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): ORR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): ORR
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): ORR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): ORR
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): DOR
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): DOR
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): DOR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): DOR
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): DOR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): DOR
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): TTR
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): TTR
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): TTR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): TTR
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): TTR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): TTR
Временное ограничение: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Временное ограничение: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Следователи

  • Директор по исследованиям: Clinical Trials, Hoffmann-La Roche

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Общие публикации

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

3 мая 2016 г.

Первичное завершение (Оцененный)

30 июня 2027 г.

Завершение исследования (Оцененный)

30 июня 2027 г.

Даты регистрации исследования

Первый отправленный

4 января 2016 г.

Впервые представлено, что соответствует критериям контроля качества

7 января 2016 г.

Первый опубликованный (Оцененный)

8 января 2016 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

23 сентября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

18 сентября 2026 г.

Последняя проверка

1 сентября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • RXDX-101-03
  • CO40778 (Другой идентификатор: Hoffmann-La Roche)
  • 2023-505088-35-00 (Ктис)
  • 2023 (Грант/контракт NIH США)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться